[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351868-105":59,"doc-detail-351868-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tissue-agnostic-targeting-in-solid-tumors-a-prisma-compliant-meta-analysis-of-efficacy-safety-and-resistance-determinants-across-histologies","Tissue-Agnostic Targeting in Solid Tumors - A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies","","Biomarker-driven tissue-agnostic oncology aligns therapies with shared molecular markers, but evaluation is challenged by assay variability, the rigor of control arms, and non-proportional hazards. This PRISMA-compliant review quantifies efficacy and safety and identifies determinants of resistance across histologies, integrating consistent estimands. A systematic review and random-effects meta-analysis of 38 studies (15,018 participants) estimates time-to-event hazard ratios with 95% CIs and uses restricted mean survival when assumptions fail.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tissue-agnostic-targeting-in-solid-tumors-a-prisma-compliant-meta-analysis-of-efficacy-safety-and-resistance-determinants-across-histologies/351868/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tissue-agnostic-targeting-in-solid-tumors-a-prisma-compliant-meta-analysis-of-efficacy-safety-and-resistance-determinants-across-histologies/351868.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the review?","Question",{"text":112,"@type":113},"To quantify and compare efficacy and safety and to identify determinants of resistance for biomarker-matched, tissue-agnostic therapies across histologies using PRISMA-compliant methods.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were outcomes analyzed when proportional hazards assumptions were violated?",{"text":117,"@type":113},"Hazard ratios with 95% confidence intervals were used for time-to-event outcomes, and restricted mean survival times were applied when proportional hazards assumptions were not met.",{"name":119,"@type":110,"acceptedAnswer":120},"Which therapies showed benefit in specific biomarker-defined settings?",{"text":121,"@type":113},"Trastuzumab deruxtecan improved response and survival in HER2-positive gastric/GEJ cancers and HER2-low metastatic breast cancer; PD-1 blockade improved PFS and five-year overall survival in MSI-H/dMMR settings; dostarlimab plus chemotherapy improved outcomes in endometrial cancer across dMMR/MSI-H and mismatch repair–proficient disease; encorafenib-based regimens reduced progression and death in BRAF V600E metastatic colorectal cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351868,1790728212,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":138,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":26,"preview_page_count":19,"preview_urls":144},4398046744996,"[http://doi.org/10.32604/or.2026.077965](http://doi.org/10.32604/or.2026.077965)  \nREVIEW  \nTissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies  \nMarwa Balaha 1 , Saad A. Aldosari2 , Ahmed A. Alamer2 , Nehad Ahmed2  \nand Mohamed F. Balaha2, *  \n1Department of Pharmacy,“G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy  \n2Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia  \n*[Corresponding Author: Mohamed F. Balaha. Email: m.balaha@psau.edu.sa](Corresponding Author: Mohamed F. Balaha. Email: m.balaha@psau.edu.sa)[ ](Corresponding Author: Mohamed F. Balaha. Email: m.balaha@psau.edu.sa)[Received: 20 December 2025](Received: 20 December 2025); [Accepted: 02 April 2026](Accepted: 02 April 2026); [Published: 16 June 2026](Published: 16 June 2026)  \nABSTRACT: Objectives: Tissue-agnostic oncology personalizes treatments based on shared molecular biomarkers, addressing challenges like assay variability, control-arm rigor, and non-proportional hazards. Integrating efficacy, safety, and resistance factors with consistent estimands is essential for evaluating biomarker-matched therapies across histologies. This review aims to quantify and compare their efficacy and safety, and to identify determinants of resistance, using PRISMA-compliant methods. Methods: We conducted a systematic review and random-effects meta-analysis of 38 studies (15,018 participants), employing dual screening, standardized bias assessment, and evaluations of heterogeneity and small-study effects. Hazard ratios (HRs) with 95% CIs were estimated for time-to-event outcomes, and restricted mean survival times were used when the proportional hazards assumption was violated. Results: Trastuzumab deruxtecan improved objective response rates and extended progression-free survival (PFS) and overall survival (OS) in HER2-positive gastric and gastroesophageal junction cancers and in HER2-low metastatic breast cancer, showing longer response durations. In metastatic colorectal cancer with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR), PD-1 blockade significantly increased PFS and five-year OS despite crossover, with restricted mean survival time gains of about 11 months. In endometrial cancer, dostarlimab combined with chemotherapy improved PFS in both dMMR/MSI-H and mismatch repair–proficient disease and increased OS overall. Encorafenib-based therapies reduced progression and death in BRAFV600E metastatic colorectal cancer. Safety profiles were class-specific: PD-1 inhibitors caused fewer grade 3 or higher adverse events than chemotherapy, whereastrastuzumab deruxtecan was associated with increased interstitial lung disease (ILD) or pneumonitis and higher rates of treatment discontinuation. Conclusion: Biomarker-matched therapies confer significant survival benefits with predictable toxicities. Confidence is strongest for PD-1 inhibitors in MSI-H/dMMR tumors, trastuzumab deruxtecan in HER2-low or HER2-positive cancers, and encorafenib-based regimens in BRAF V600E metastatic colorectal cancer. Implementation should include validated assays (including reconfirmation of HER2 status), prioritize earlier treatment lines where gains are greatest, and require vigilant ILD monitoring. Head-to-head trials and assay standardization, especially for tumor mutational burden, remain priorities.  \nKEYWORDS: Tissue-agnostic therapy; PRISMA; meta-analysis; MSI-H/dMMR; PD-1 inhibitor; HER2-low; antibodydrug conjugate; interstitial lung disease; BRAF V600E; NTRK fusion  \n1 Introduction  \nPrecision oncology is increasingly guided by tissue-agnostic selection, aligning therapies with actionable biomarkers regardless of histology. Robust evidence supports this approach across microsatellite  \nCopyright © 2026 The Authors. Published by Tech Science Press. This work is licensed under a Creative Commons Att","cbCairglSNpuGOgK","https://ap.wps.com/l/cbCairglSNpuGOgK","pdf",4572701,24,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What is the main purpose of the review?\",\"answer\":\"To quantify and compare efficacy and safety and to identify determinants of resistance for biomarker-matched, tissue-agnostic therapies across histologies using PRISMA-compliant methods.\"},{\"question\":\"How were outcomes analyzed when proportional hazards assumptions were violated?\",\"answer\":\"Hazard ratios with 95% confidence intervals were used for time-to-event outcomes, and restricted mean survival times were applied when proportional hazards assumptions were not met.\"},{\"question\":\"Which therapies showed benefit in specific biomarker-defined settings?\",\"answer\":\"Trastuzumab deruxtecan improved response and survival in HER2-positive gastric/GEJ cancers and HER2-low metastatic breast cancer; PD-1 blockade improved PFS and five-year overall survival in MSI-H/dMMR settings; dostarlimab plus chemotherapy improved outcomes in endometrial cancer across dMMR/MSI-H and mismatch repair–proficient disease; encorafenib-based regimens reduced progression and death in BRAF V600E metastatic colorectal cancer.\"}]","Tissue-Agnostic Targeting in Solid Tumors - A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies | PDF",1790096361,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a99463430bf09aa9a220be98ff08382e.webp",983,1272,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d641f5b17401043868ca7a888447cd39.webp",982,1270,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c50d872431564a21c83cfe1e7040028b.webp",981,1269,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f68eb3c0370981ac567f630c95c365d.webp",980,1268]